Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aura Biosciences Inc (AURA)
NASDAQ:AURA
Holding AURA?
Track your performance easily
AURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.63 - $12.38
Previous Close$8.2
Volume612.49K
Average Volume (3M)206.13K
Market Cap
$409.60M
Enterprise Value$254.31M
Total Cash (Recent Filing)$174.38M
Total Debt (Recent Filing)$19.08M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Mar 12, 2025EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding49,951,466
10 Day Avg. Volume657,719
30 Day Avg. Volume206,134
Standard Deviation0.16
R-Squared0.00647
Alpha-0.00210
Financial Highlights & Ratios
Price to Book (P/B)2.34
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$22.43Price Target Upside173.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Aura Biosciences Inc News
PremiumCompany Announcements
Aura Biosciences Reports Q3 Financial Results
PremiumCompany Announcements
Aura Biosciences Reports Positive Phase 1 Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressInvestigators have registered over 100 patients meeting initial enrollment criteria for the Phase 3 CoMpass trial, indicating swift enrollment.
Financial OutlookThe company ended 3Q24 with $174.4M in cash and equivalents, which is considered sufficient to fund operations into the second half of 2026.
Regulatory AdvancementsAura has received EMA authorization to start enrollment in the EU for the ongoing Phase 3 CoMpass trial in early-stage choroidal melanoma.
Bears Say
Clinical Trial ResultsNone of the three high grade patients who received bel-sar with light activation demonstrated a complete response, though 2 out of 3 demonstrated tumor shrinkage.
Regulatory ApprovalThe approval for the Phase 3 CoMpass trial in the EU was granted later than anticipated, though timelines for data readout remain unchanged.
Trial Design And EvaluationThe trial design specifies a 56-day safety follow-up, making it unlikely to assess the durability of response, which is a key metric in this treatment.
---
Ownership Overview
2.91% Insiders
20.45% Mutual Funds
50.55% Other Institutional Investors
17.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $6.63 and its highest was $12.38 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Currently, no data Available
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Mar 12, 2025 which is in 80 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Nov 12, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.441 by $0.021.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -$0.44.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 49,951,466 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.441. Following the earnings report the stock price went down -3.005%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Among the largest hedge funds holding Aura Biosciences Inc’s share is Matrix Capital Management Company, LP. It holds Aura Biosciences Inc’s shares valued at 62M.
---
Aura Biosciences Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.43 (173.54% Upside)
$22.43 (173.54% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $288.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.07%
12-Months-Change
Fundamentals
Return on Equity
-50.99%
Trailing 12-Months
Asset Growth
14.23%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
---
AURA Stock 12 Month Forecast
Average Price Target
$22.43
▲(173.54% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Mersana Therapeutics
―
Alaunos Therapeutics
―
Cellectar Biosciences
―
Best Analysts Covering AURA
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-10.32%
reiterated a buy rating last month
Copying Julian Harrison's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -10.32% per trade.
---